INO
Inovio Pharmaceuticals, Inc.
$1.16
-0.06 (-4.92%)
At close · Jul 6
Market Cap
$95.44M
Shares
82,273,237
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.16
Open$1.21
Day$1.15–1.23
52W$1.03–2.98
Avg vol 30d1.7M
Short int16.2M · 19.7% float · 10.8d
Short vol23%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−32% below
◦
Price vs 50-day avg
−3% below
◦
RSI (14)
50 · neutral
+
MACD trend
positive
−
52-week position
7% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $1 › 200d $2 — 200d above 50d
◦
Institutional flow
2 of 100 funds reported for Jun 30 · net 0 sh shares
◦
Insider flow
No net insider activity over 90 days
+
Short interest
19.69% of float · ▼ -0.4% MoM · 10.8 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
100 holders — mid 2-yr range
Fundamentals
Strong
+
Revenue growth
+1496% Y/Y
+
EPS growth
+54% Y/Y
−
Free cash flow
$-88.9M
+
Balance sheet
net cash $44.3M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 14, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 13, 2026
Operational net cash burn
· second quarter of 2026
Initiated
$18M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−32% below
Bearish
Price vs 50-day avg
−3% below
Neutral
RSI (14)
50 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
7% · near low
Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
2 of 100 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.69% of float · ▼ -0.4% MoM · 10.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
100 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 7%
52-wk high $3
vs 200-day avg -32%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INO
this stock
Inovio Pharmaceuticals, Inc.
|
$95.44M | -33.3% | +288.0% | — | 19.7% |
|
AKTX
Akari Therapeutics Plc
|
$998.08B | -5.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.41B | +16.8% | +46.2% | 31.4 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INO | +5.5% | +0.0% | -25.6% | +5.5% | -33.3% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +2.4% | +0.8% | -33.9% | +4.9% | -43.5% |